Colchicum (Meadow saffron) for Muscles and Joints

by | Nov 17, 2015

Colchicum autumnale is a beautiful small perennial plant that is native to the British Isles, Europe, the Baltic States and New Zealand. It typically flowers in the autumn after the leaves have disappeared. The seeds and bulb and to lesser extent the flowers of Colchicum contain Colchicine, which is used in the treatment of gout. The leaves are the source of another medicinal chemical known as Thiocolchicoside (TCC), which has been found to produce effective muscle relaxation, as well as analgesic and anti-inflammatory activities without any sedative side-effects. Clinical trials have demonstrated TCC to be a safe and effective muscle relaxant.
TCC is a natural sulfur containing Glycoside that produces the effective muscle relaxation. It removes or significantly reduces the contracture of Central origin: in spasticity, it decreases the passive resistance of muscle to stretch and reduces or removes residual contracture. Its myorelaxant action occurs also on the abdominal, or visceral muscles.
TCC is devoid of any harmful paralyzing effect. It provides its muscle relaxing benefits through the central nervous system and not by a paralysis of the motor plate. Biochemical research has shown that TCC has a selective activating affinity of  for gamma-aminobutyric acid (GABA) A receptors, as well as Glycine receptor activity. It therefore does not affect voluntary motility, causes no respiratory paralysis and avoids any risk of harm to the respiratory system. Additionally, TCC has no negative influence on the cardiovascular muscles.
In November 2004, Dr. Hansen traveled to Paris, France, to train with Dr. Jacques LeCoz, MD, where he learned to use Colchicum Thiocholchicoside in small doses as part of a combination in mesotherapy injections for multiple musculoskeletal disorders, including Spasms, Neck and Back Pain, Trigger Point Therapy, Tendonitis, TMJ, Strains and Sprains of Ligaments,  Myofacial Pain Syndromes and more.
Dr. Hansen says “The healing relief and benefits of Colchicum Thiocolchicoside accomplished via Trigger Point Injection Therapy and Mesotherapy have been nothing short of amazing.” If you are suffering from any acute or chronic musculoskeletal pain, please call to learn more and find out if this therapy is right for you.
 
References

  1. Patat A, Klein MJ. Effects of acute and repeated doses of twomuscle relaxants chlormezanone and thiocolchicoside, onvigilance and psychomotor performance of healthy volunteers. Hum Psychopharmacol 1991;6:285-92.
  2. Janbroers JM. Review of the toxicology, pharmacodynamicsand pharmacokinetics of thiocolchicoside, a GABA-agonistmuscle-relaxant with anti-inflammatory and analgesic actions. Acta Ther 1987;13:221-50.
  3. Eandi M, Genazzani E, Della Pepa C, Basso G. Ricerca farmacoepidemiologica in fase IV sulla efficacia e tollerabilita’ delprodotto „Muscoril ®. Ort Traum Oggi 1992;12:138-48.
  4. Marcel C, Rezvani Y, Revel M. Evaluation of thiocolchicosideas monotherapy in low back pain. Results of a randomized study versus placebo. [Article in French] Presse Med1990;19:1133-6.
  5. Ventura R, Leonardi M, Mastropaolo C, Picci M, Vescovini R.Studio clinico controllato sull’uso del thiocolchicoside nellapatologia ortopedica. Ortop Traumatol Oggi 1983;3:65-73
  6. The efficacy of thiocolchicoside (Muscoril®) in the treatment of acute cervical myofascial pain syndrome: a single-blind, randomized, prospective, phase IV clinical study. Department of Physical Medicine and Rehabilitation, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

14 + 5 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });